

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI766038

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
PILLAR BIOSCIENCES, INC.	01/13/2025
RECEIVING PARTY DATA	
Company Name:	SCOF BLOCKER AIV, L.P.
Street Address:	104 Field Point Road
City:	Greenwich
State/Country:	CONNECTICUT
Postal Code:	06830
PROPERTY NUMBERS Total: 6	
Property Type	Number
Patent Number:	10011869
Patent Number:	10221448
Patent Number:	11104945
Patent Number:	11913069
Patent Number:	9605305
Application Number:	17936307
CORRESPONDENCE DATA	
Fax Number:	6173417729
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6173417729
Email:	katarzyna.gaysunas@morganlewis.com
Correspondent Name:	Katarzyna Gaysunas
Address Line 1:	1 Federal St
Address Line 2:	c/o Morgan, Lewis & Bockius LLP
Address Line 4:	Boston, MASSACHUSETTS 02110-1726
NAME OF SUBMITTER:	Katarzyna Gaysunas
SIGNATURE:	/Katarzyna Gaysunas/
DATE SIGNED:	01/17/2025
Total Attachments: 8	

source=Soleus Capital_Pillar - IP Security Agreement (Patent) (Executed)#page1.tiff
source=Soleus Capital_Pillar - IP Security Agreement (Patent) (Executed)#page2.tiff
source=Soleus Capital_Pillar - IP Security Agreement (Patent) (Executed)#page3.tiff
source=Soleus Capital_Pillar - IP Security Agreement (Patent) (Executed)#page4.tiff
source=Soleus Capital_Pillar - IP Security Agreement (Patent) (Executed)#page5.tiff
source=Soleus Capital_Pillar - IP Security Agreement (Patent) (Executed)#page6.tiff
source=Soleus Capital_Pillar - IP Security Agreement (Patent) (Executed)#page7.tiff
source=Soleus Capital_Pillar - IP Security Agreement (Patent) (Executed)#page8.tiff

PATENT SECURITY AGREEMENT

This **PATENT SECURITY AGREEMENT** (this “**Agreement**”), dated as of January 13, 2025, is made by Pillar Biosciences, Inc., a Delaware corporation, with a principal place of business at 9 Strathmore Road, Natick, MA 01760 (the “**Grantor**”), in favor of SCOF Blocker AIV, L.P. (together with its successors and assigns, the “**Lender**”). Capitalized terms used but not otherwise defined herein shall have the meaning given to them in the Credit Agreement (as defined below).

WHEREAS, the Grantor is party to that certain Credit and Security Agreement dated as of January 13, 2025, by and among the Grantor, the guarantors from time to time party thereto and the Lender (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), pursuant to which the Grantor granted a security interest to the Lender in all of Grantor’s right, title and interest in and to the Collateral, including the Patent Collateral (as defined below), and is required to execute and deliver this Agreement.

NOW, THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, subject to the terms and conditions of the Credit Agreement, to evidence further the security interest granted by Grantor to the Lender pursuant to the Credit Agreement, Grantor hereby grants to the Lender a security interest in all of Grantor’s right, title and interest in and to the following, in each case whether now owned or existing or hereafter acquired or arising and wherever located (collectively, the “**Patent Collateral**”):

1. all patents and patent applications (including provisional patent applications) and industrial designs under any domestic or foreign law, and all reissues, continuations, continuations-in-part, divisionals, extensions, renewals, revisions and reexamination thereof, and all inventions and improvements described and claimed therein (including the issued patents and patent applications set forth on Schedule A annexed hereto);
2. all rights to sue or otherwise recover for any past, present and future infringement, dilution, misappropriation, or other violation or impairment of any of the foregoing; and
3. all license fees, royalties, income, payments, claims, damages and proceeds of suit, now or hereafter due and/or payable with respect thereto.

Notwithstanding anything herein to the contrary, in no event shall the Patent Collateral include, and the Grantor shall not be deemed to have granted a security interest in, any of the Grantor’s rights or interests in any Excluded Assets (but shall include all products, substitutions, replacements and Proceeds thereof to the extent not otherwise constituting Excluded Assets).

Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Credit Agreement. All the terms of the Credit Agreement are hereby incorporated by reference. In the event that any provision of this Agreement is deemed to conflict with the Credit Agreement, the provisions of the Credit Agreement shall control.

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER AND ALL CLAIMS AND CONTROVERSIES ARISING OUT OF THE SUBJECT MATTER HEREOF WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE, SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAW PROVISIONS THAT WOULD RESULT IN THE APPLICATION OF ANY OTHER LAW (OTHER

THAN ANY MANDATORY PROVISIONS OF LAW RELATING TO THE LAW GOVERNING PERFECTION AND THE EFFECT OF PERFECTION OF THE SECURITY INTEREST).

This Agreement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Agreement by facsimile transmission or other electronic transmission (e.g., a “.pdf” or “.tif” file) shall be effective as delivery of a manually executed counterpart hereof. The words “execute”, “execution”, “signed”, “signature” and words of like import in or related to this Agreement shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Lender, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act or any other similar state laws based on the Uniform Electronic Transactions Act.

[The remainder of this page is intentionally left blank.]

IN WITNESS WHEREOF, Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

PILLAR BIOSCIENCES, INC.

as Grantor

By:  Signed by:
Name: Gang Song
Title: Chief Executive Officer

Accepted and Agreed:

SCOF BLOCKER AIV, L.P.

as the Lender

By: Soleus Credit GP I, LLC, as General Partner

By: 
Name: Steven J. Musumeci
Title: Chief Operating Officer

SCHEDULE A
to
PATENT SECURITY AGREEMENT
See Attached.

Pillar (113970) Active Matter List 12-18-24						
FILE NUMBER	COUNTRY	APP NO	GRANT		TITLE	MATTER TYPE
			PATENT NO	DATE		
113970.8001.AU01	Australia	2016229372	2016229372	2020-05-14	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.CA01	Canada	2,978,709	2978709	6/4/2024	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.CH01	Switzerland	16762140.8	3265590	2019-01-02	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.CN01	China	201680014257.X	ZL201680014257.X	2019-09-13	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.DE01	Germany	16762140.8	3265590	2019-01-02	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.EP01	European Patent Office	16762140.8	3265590	2019-01-02	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.ES01	Spain	16762140.8	ES2718765T3	2019-01-02	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.FR01	France	16762140.8	3265590	2019-01-02	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.GB01	United Kingdom	16762140.8	3265590	2019-01-02	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.IT01	Italy	16762140.8	502019000021125	2019-01-02	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.JP01	Japan	2017-543754	6588560	2019-09-20	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.KR01	Republic of Korea	10-2017-7028257	10-2607479	2023-11-24	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility
113970.8001.SG01	Singapore	11201707154S	11201707154S	2020-09-30	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility

113970.8001.US01	United States of America	15/057,343	10,011,869	2018-07-03	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility	Issued
113970.8001.US02	United States of America	15/396,132	10,221,448	2019-03-05	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility	Issued
113970.8001.US03	United States of America	16/290,736	11,104,945	2021-08-31	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility	Issued
113970.8001.US04	United States of America	17/458,162	11,913,069	2024-02-27	SELECTIVE AMPLIFICATION OF OVERLAPPING AMPLICONS	Utility	Issued
113970.8002.AU01	Australia	2016289369	2016289369	2020-10-15	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.CA01	Canada	2,991,401	2991401	2023-12-05	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.CH01	Switzerland	16787706.7	3134554	2018-08-29	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.CN01	China	201680001111.1	Z1201680001111.1	2017-12-05	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.DE01	Germany	16787706.7	602016005211.3	2018-08-29	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.EP01	European Patent Office	16787706.7	3134554	2018-08-29	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.ES01	Spain	16787706.7	3134554	2018-08-29	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.FR01	France	16787706.7	3134554	2018-08-29	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.GB01	United Kingdom	16787706.7	3134554	2018-08-29	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.IT01	Italy	16787706.7	502018000035948	2018-08-29	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued

113970.8002.JP01	Japan	2016-567756	6310099	2018-03-23	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.KR01	Republic of Korea	10-2018-7003604	10-2625365	2024-01-11	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.SG01	Singapore	11201800039P	11201800039P	2021-05-28	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.TW01	Taiwan	105131614	1707041	2020-10-11	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8002.US01	United States of America	15/184,014	9,605,305	2017-03-28	METHOD FOR REDUCING PRIMER-DIMER AMPLIFICATION	Utility	Issued
113970.8003.EP01	European Patent Office	22877530.0			PERSONALIZED CANCER LIQUID BIOPSIES USING PRIMERS FROM A PRIMER BANK	Utility	Pending
113970.8003.JP01	Japan				PERSONALIZED CANCER LIQUID BIOPSIES USING PRIMERS FROM A PRIMER BANK	Utility	Pending
113970.8003.US01	United States of America	17/936,307			PERSONALIZED CANCER LIQUID BIOPSIES USING PRIMERS FROM A PRIMER BANK	Utility	Pending

PATENT